Supportive Care

Patients with preexisting inflammatory bowel disease have a significantly higher risk of developing gastrointestinal adverse events during treatment with an immunotherapybased anticancer regimen than those without inflammatory bowel disease.

Douglas W. Blayney, MD, discusses phase II results of the combination of pegfilgrastim and plinabulin, as well as the importance of controlling chemotherapy-induced neutropenia for patients.

Use of immune checkpoint inhibitors correlates with high incidence of endocrinopathies, especially anti–CTLA-4 therapy.